The FDA grants accelerated approval to AstraZeneca's breast cancer drug camizestrant (Etcamah) in combination with a CDK4/6 inhibitor, marking a landmark shift to ctDNA-guided treatment before radiographic progression. The decision diverges from an April 2026 advisory committee rejection that flagged concerns over the SERENA-6 trial design. Although the trial showed a 56% reduction in progression risk, AstraZeneca must conduct confirmatory studies to verify clinical benefit.
FDA camizestrant approval
- ▪AstraZeneca's camizestrant is indicated for use in combination with a CDK4/6 inhibitor when ESR1 resistance mutations are detected during first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor
- ▪The FDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader camizestrant, marketed as Etcamah, on September 4, 2026, for treating hormone receptor-positive, HER2-negative breast cancer
- ▪AstraZeneca estimates that approximately 30% of the 37,000 hormone receptor-positive metastatic breast cancer patients treated with endocrine therapies and CDK4/6 inhibitors in the United States may develop ESR1 mutations
- ▪The FDA approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with ESR1 mutations eligible for treatment with AstraZeneca's camizestrant
ctDNA-guided treatment paradigm
- ▪Jefferies analysts stated that the FDA approval of AstraZeneca's camizestrant validates a new treatment paradigm of circulating tumor DNA-guided intervention before radiographic progression
- ▪The FDA approval of AstraZeneca's camizestrant marks the first cancer treatment approval where therapy is switched based on resistance mutations detected by circulating tumor DNA in the blood rather than radiographic progression
- ▪AstraZeneca submitted additional circulating tumor DNA analyses showing that total circulating tumor DNA levels were reduced by 99% in the camizestrant arm by Week 8, compared to a 64% increase in the control arm
SERENA-6 trial design controversy
- ▪The Phase III SERENA-6 trial did not allow patient crossover to AstraZeneca's camizestrant, and only 14% of patients in the control arm received other oral selective estrogen receptor degraders for subsequent treatment
- ▪In the Phase III SERENA-6 trial, median progression-free survival improved from 9.2 months for patients remaining on an aromatase inhibitor to 16 months for those switching to AstraZeneca's camizestrant
- ▪The FDA approval of AstraZeneca's camizestrant was based on results from the Phase III SERENA-6 trial, which showed switching to camizestrant reduced the risk of disease progression or death by 56%
- ▪The FDA initially criticized the Phase III SERENA-6 trial design because the trial did not compare the early treatment switch approach to the standard practice of waiting until radiographic disease progression
Advisory committee rejection
- ▪In April 2026, the FDA's Oncologic Drugs Advisory Committee voted against recommending AstraZeneca's camizestrant, stating the Phase III SERENA-6 trial did not establish a clinically meaningful benefit
- ▪Members of the FDA's Oncologic Drugs Advisory Committee expressed concern that the Phase III SERENA-6 trial design was flawed because it did not offer enough control-arm patients an oral selective estrogen receptor degrader as second-line treatment
Accelerated approval conditions
- ▪The prescribing information for AstraZeneca's camizestrant includes a boxed warning for the risk of arrhythmia due to QTc interval prolongation when used with QTc-prolonging drugs, including ribociclib
- ▪Because it is unconfirmed whether intervening before radiographic progression translates to clinical benefit, the FDA has required AstraZeneca to conduct confirmatory studies to verify the clinical benefit of camizestrant
- ▪AstraZeneca is expected to provide confirmatory evidence for camizestrant from the Phase III SERENA-4 trial, which is evaluating camizestrant as a first-line treatment and expects topline results in 2026
Debatable claims
- ▪The FDA should not approve drugs rejected by its advisory committees
- ▪The FDA was justified in approving AstraZeneca's camizestrant
Story comments
Loading comments…